适合移植的多发性骨髓瘤患者中不可持续可测量残留病阴性的预测因素
研究纳入267例新诊断适合移植的多发性骨髓瘤患者,均经下一代流式细胞术达到可测量残留病(MRD)阴性。中位随访73个月后,111例(42%)出现MRD再现和/或疾病进展。诊断时ISS 3期和≥0.01%循环肿瘤细胞(CTCs)以及诱导后未达MRD阴性可预测MRD再现和/或疾病进展。
要点
- 诊断时ISS 3期和≥0.01% CTCs是预测MRD再现和/或疾病进展的预后因素。
- 诱导治疗后未达到MRD阴性也预测MRD再现和/或疾病进展风险更高。
- 具有0、1、≥2个风险因素(ISS 3、≥0.01% CTCs、晚期MRD阴性)的患者5年MRD再现和/或疾病进展率分别为16%、33%、57%(P < .001)。
核心结论
- 诊断时ISS 3期、≥0.01% CTCs以及诱导后未达MRD阴性可预测适合移植的多发性骨髓瘤患者MRD再现和/或疾病进展。
- 这些易于测量的风险因素有助于细化选择在MRD阴性后停止治疗正在临床试验中研究的患者。
研究设计与样本
- 研究纳入GEM2012MENOS65和GEM2014MAIN临床试验中267例新诊断适合移植的多发性骨髓瘤患者,均经下一代流式细胞术达到MRD阴性。
- 自首次MRD阴性评估起中位随访73个月。
主要发现
- 267例患者中111例(42%)出现MRD再现和/或疾病进展。
- 诊断时仅ISS 3期和≥0.01% CTCs可预测MRD再现和/或疾病进展。
- 诱导后未达到MRD阴性也预测MRD再现和/或疾病进展风险更高。
- 具有0、1、≥2个风险因素(ISS 3、≥0.01% CTCs、晚期MRD阴性)的患者5年MRD再现和/或疾病进展率分别为16%、33%、57%(P < .001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of measurable residual disease (MRD) negativity as a biomarker to stop treatment is being investigated in transplant-eligible patients with multiple myeloma (MM). Thus, it is important to identify risk factors of MRD resurgence and/or progressive disease (PD) among patients achieving undetectable MRD to avoid undertreating them. Here, we studied 267 newly diagnosed transplant-eligible patients with MM enrolled in the GEM2012MENOS65 and GEM2014MAIN clinical trials who achieved MRD negativity by next-generation flow cytometry. After a median follow-up of 73 months since the first MRD negative assessment, 111 of the 267 (42%) patients showed MRD resurgence and/or PD. The only prognostic factors at diagnosis that predicted MRD resurgence and/or PD were an International Staging System (ISS) 3 and the presence of ≥0.01% circulating tumor cells (CTCs). Failure to achieve MRD negativity after induction also predicted higher risk of MRD resurgence and/or PD. Patients having 0 vs 1 vs ≥2 risk factors (ISS 3, ≥0.01% CTCs, and late MRD negativity) showed 5-year rates of MRD resurgence and/or PD of 16%, 33%, and 57%, respectively (P < .001). Thus, these easily measurable risk factors could help refine the selection of patients for whom treatment cessation after MRD negativity is being investigated in clinical trials. This trial was registered at www.clinicaltrials.gov as NCT01916252 and NCT02406144.
引用
- Guerrero C, Puig N, Cedena MT, et al. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma. Blood. 2024. PMID: 38048552. doi:10.1182/blood.2023022083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。